



2024 Annual Conference

Hosted by



**European Committee
of the Regions**

FOURTH SESSION: Friday 29th of November – 11:30 to 13:00

Shaping the Future: A Dialogue on EU Partnerships in Health

Introduction

KATHRIN KAPFINGER – DG RTD, G4 Missions and Partnerships

Interactive panel discussion

- *MAGALI POINOT – Innovative Health Initiative*
- *JOËL GROENEVELD – Fonds de la Recherche Scientifique, ERA4Health*
- *ULRICA DOHNHAMMAR – Swedish Research Council, JPIAMR secretariat, OHAMR*
- *GIOVANNI NICOLETTI – Italian Ministry of Health / JANFP4 Health*

Moderator: *JOHAN HANSEN – Nivel, WP4 leader*



European
Commission

#HorizonEU

HORIZON EUROPE

THE EU
RESEARCH & INNOVATION
PROGRAMME

2021 – 2027

EUROPEAN PARTNERSHIPS

THCS Annual Conference
Shaping the Future: A Dialogue on EU
Partnerships in Health
29 November 2024

Kathrin Kapfinger
G.4 – Common Missions & Partnerships
Service
DG Research & Innovation

Research
and
Innovation

European Partnerships – what and why

European Partnerships are strategic instruments which enable long-term collaborations between the Union and public and/or private partners to tackle common challenges through the co-design and implementation of joint R&I programmes



STRATEGIC ORIENTATION

Foster directionality of funding in line with EU policy priorities



CREATING CRITICAL MASS

- Avoid fragmentation and duplication of R&I efforts
- Achieve greater scale and impact



FOSTERING ECOSYSTEMS

- Integrated value chains and ecosystems
- Integrative activities outside of funding



New approach under Horizon Europe

New generation of objective-driven and more ambitious partnerships in support of agreed EU policy objectives

Key Features

- **Increased ambitions**
- **Simplified architecture and toolbox**
- **Common set of criteria for the entire life-cycle (Horizon Europe regulation Article 10 and Annex III)**

CO-PROGRAMMED

Based on Memoranda of Understanding/contractual arrangements;
implemented independently by the partners and by Horizon Europe

CO-FUNDED

Based on a joint programme agreed and implemented by partners;
commitment of partners for financial contributions and additional activities

INSTITUTIONALISED

Based on long-term dimension and need for high integration; partnerships based on Art 185/187 of TFEU and the EIT legal acts for 2021-2027



Budgetary commitments to the first set of European Partnerships*

PARTNERSHIPS

50
European Partnerships

€25 bn
Estimated commitments from Horizon Europe*

40%
Of Horizon Europe's Pillar II budget*

Over 25%
of Horizon Europe total*

€36 bn
Estimated total commitments from partners other than the Union*

**Not including partnerships that will be launched in 2025-2027*



European Partnerships under Horizon Europe

PILLAR II - Global challenges & European industrial competitiveness

PILLAR III - Innovative Europe

CLUSTER 1: Health	CLUSTER 2: Culture, Creativity, Inclusive Societies	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bio-economy, Agriculture, Env...	EUROPEAN INNOVATION ECOSYSTEMS
Innovative Health Initiative	Resilient Cultural Heritage*	Chips (formerly KDT)	Clean Hydrogen		Innovative SMEs
Global Health Partnership	Social Transformations and Resilience*	Smart Networks & Services	Clean Aviation	R&I in the Mediterranean Area (PRIMA, Art. 185)**	
Transforming Health and Care Systems		High Performance Computing	Single European Sky ATM Research 3	Biodiversa+	EIT
Chemicals risk assessment		European Metrology (Art. 185)	Europe's Rail	Climate Neutral, Sustainable & Productive Blue Economy	InnoEnergy
ERA for Health		AI-Data-Robotics	Connected and Automated Mobility (CCAM)	Water4All	Climate
Rare diseases		Photonics	Batt4EU	Animal Health & Welfare	Digital
One-Health Anti Microbial Resistance*		Made in Europe	Zero-emission waterborne transport	Accelerating Farming Systems Transitions	Food
Personalised Medicine		Clean steel – low-carbon steelmaking	Zero-emission road transport	Agriculture of Data*	Health
Pandemic Preparedness*		Processes4Planet	Built4People	Safe & Sustainable Food System	Raw Materials
Brain Health*		Global competitive space systems	Solar Photovoltaics*	Forests and Forestry for a sustainable Future*	Manufacturing
		Innovative Materials for EU (I AM for EU)*	Clean Energy Transition		Urban Mobility
		Virtual Worlds*	Driving Urban Transitions		Cultural and Creative Industries*
		Textiles of the Future*			Water, Marine and Maritime Sectors and Ecosystem*
		Raw Materials for the Green and Digital Transition*			

■ Institutionalised Partnerships (Art. 185/7)

■ Institutionalised partnerships / EIT KICs

■ Co-Programmed

■ Co-Funded

■ Proposed new candidate European Partnerships under the Horizon Europe strategic plan 2025-2027

* Not yet launched

** Direct continuation of a H2020 partnership

CROSS-PILLARS I AND II

European Open Science Cloud



Strategic Coordinating Process

- New governance framework for European Partnerships
- Supports evidence-based policymaking for partnerships and a strategic vision of the landscape
- Allows a consolidated view on the progress made by European
- To implement the strategic coordinating process, the Commission has set up:
 - The **Partnership Knowledge Hub (PKH)** - a formal structure for collaboration between the Commission and the authorities responsible for the national coordination and participation in EU R&I partnerships from Member States and Associated Countries
 - The **Biennial Monitoring Report (BMR)** to create more harmonised monitoring and reporting framework for European Partnerships
 - The **Partnership Stakeholder Forum**, an annual event providing a venue for networking, broadening engagement, sharing of experiences and discussing policy and practical dimensions related to partnerships






Avenues for synergies and collaboration

- Synergies between partnerships and other relevant instruments are essential to foster holistic and integrated approaches
- No top-down/one-size-fits-all solutions
- Some examples:
 - Clean Planet Inter-Partnership Assembly: harmonise and align activities of different partnerships
 - Joint calls between different partnerships and/or Missions
 - Collaborations with regional actors
 - Standing Committee on Agricultural Research



What does the future hold?

- A lot of uncertainties: discussions on FP10 are still preliminary
- Reflections along 4 building blocks



Further resources

- [European Partnerships website](#) on europa.eu:
 - Published partnership proposals and contact points
 - Reports (e.g. Biennial Monitoring Report, report on coherence and synergies)
 - Infographics
 - Latest news
- [ERA Learn](#)
 - Large variety of detailed information on the financial management of European Partnerships, guidelines on SRIA development, etc.
- RTD-EUROPEAN-PARTNERSHIPS@ec.europa.eu



Thank you!





The Innovative Health Initiative – IHI JU


Bold collaborations, Transforming health

Magali Pointot

29.11.2024 • THCS Annual Conference 2024 • Committee of Regions, Brussels, Belgium








What is IHI?



IHI IS EUROPE'S PARTNERSHIP FOR HEALTH

IHI is a **collaboration** between the EU and the biopharmaceutical, biotechnology, digital health and medical technology sectors, as well as academics, patients, regulators and other healthcare professionals.

Associations	Represent	Mission/Vision
	Pharmaceutical industry	To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
	Medical imaging, radiotherapy, health ICT and electromedical ind.	COCIR's key objective is to promote free worldwide trade of innovative medical technology while maintaining the competitiveness of the European medical imaging, radiotherapy, electromedical and health ICT industries.
	Medical technology industry	Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.
	Vaccine industry	To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.
	Biotech industry	Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.

IHI Objectives

Improve our **understanding of the factors that affect health** and the **treatment of priority disease areas**



Integrate fragmented health research and innovation efforts by bringing together health industry sectors and other stakeholders to **improve prevention, diagnosis, treatment, and management of diseases**, focusing on unmet public health needs



Demonstrate the feasibility of **people-centred, integrated healthcare solutions** which draw on various technologies and sectors



Exploit the full potential of **digitalisation and data exchange** in research and care, while respecting **privacy** legislation



Develop methodologies for a comprehensive assessment of the added value of **innovative and integrated health care solutions**



By achieving these, IHI aims to

Deliver **safe, effective health innovations** that cover the entire spectrum of care, particularly in areas where there is an unmet public health need

Make Europe's health industries **globally competitive**

Turn health research and innovation into **real benefits** for patients and society

How?

By supporting projects, selected following **calls for proposals**, that **bring diverse stakeholders & sectors together**

Any legal entity or international organisation regardless of its place of establishment can **participate**

Any organisation established in the EU or a country associated to Horizon Europe is **eligible to receive IHI funding***

**IHI two-stage calls: companies identified in the call topic are not eligible to receive IHI funding*

IHI involves multiple healthcare stakeholders

Analysing the composition of the IHI consortia, all IHI projects (20 projects = 100%) involve more than two types of healthcare stakeholders as project participations. This exceeds the targets set for 2023 (55%) and 2025 (60%)



€473M

Public and private commitments (all funds incl. IKAA)



20

Signed grant agreements




Example of project CLAIMS - 15 multi-stakeholder participations


CLAIMS addresses Multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system. It currently affects around 3 million people worldwide. There is no cure, although there are treatments that can slow the progress of the disease. The aim of the CLAIMS project is to develop a diagnostic platform that would offer clinicians a holistic overview of the MS patient. The platform would predict how the patient's MS would likely progress with different treatments. The project brings together health care professional organisations/providers, SMEs, Large companies, NGOs and leading academics. Ultimately, the project hopes to validate the platform and submit it to medicines regulators for approval.



Data export
09/2024



IHI brings together several industrial sectors



Analysing the composition of the IHI consortia, almost all of them (19 out of 20 projects = 95%) bring together private members and/or contributing partners (or their affiliated or constituent entities) from two or more technology sectors.

This exceeds the targets set for 2023 (60%) and 2025 (65%).


Example of project IMAGIO

16 academic and 15 industrial stakeholders active in 3 sectors



The IMAGIO project focuses on an approach called interventional oncology (IO) which targets cancer cells more precisely, thereby sparing healthy cells from the toxic effects of many treatments. In IO, miniaturized instruments (including biopsy needles, electrodes or catheters) are inserted into the patient's body via minimally invasive access routes. IO can be used to deliver diverse types of cancer treatments, including surgery, radiotherapy, chemotherapy and immunotherapy. The project brings together representatives of the medical technology, pharmaceutical and biopharmaceutical sectors as well as leading academic sectors. Together, they will explore and demonstrate how next generation IO imaging techniques can be applied to cancer research and treatment, from laboratory studies to clinical trials.

Industrial stakeholders




How are call topics generated?



What does an IHI project look like?

- Precompetitive
- Contributes directly to IHI's objectives (legislation + SRIA)
- Addresses an unmet public health need
- Cross sectoral
- Public – private in nature, leveraging contributions from:
 - Members of the IHI industry associations (EFPIA –including Vaccine Europe-, COCIR, MedTechEurope and EuropaBio)
 - EU public funding – Horizon Europe
 - Contributing Partners (approved by Governing Board) where relevant
- Innovative and ambitious
- To deliver clearly-described impacts on society, the economy and science

Portfolio overview per Specific Objective



Synergies: IHI and the EU policies / initiatives

- Horizon Europe: Cancer Mission, EU partnerships, EIT Health, etc.
- Europe's Beating Cancer Plan
- The new Industrial Strategy for Europe
- The Pharmaceutical Strategy for Europe
- The European Health Data Space (EHDS)
- Green Deal Strategy
- Digital/AI strategy, etc.
- UN Sustainable Development Goal 3 on ensuring healthy lives and promoting well-being for all at all ages

Joint priorities – aligned resources



Understanding of cancer

IMMuCan , PERSIST SEQ, ...

Prevention and early detection

No Directed effort - IDERHA

Diagnosis and treatment

*IMAGIO, GUIDE.MRD,
PIONEER/OPTIMA, theranostics*

Quality of life for patients and their families

*No directed effort – IMAGIO,
SISAQOL-IMI*

IHI Cancer projects – €145 million investment

Industry / CP contribution: 68 million €

IHI financial contribution: 77 million €

Contributing partners


Industry members



Public organisations & SME



Research orgs, Patients, Healthcare, Regulators, ...



Step in IHI opportunities!

- Calls for proposals – Official launch mid-January 2025
 - ✓ Call 9 – a single-stage, **applicant driven call** with **5 topics** aligned with the five specific objectives of the IHI research agenda
 - ✓ Call 10 - two-stage call with **3 topics** under consideration: **Digital labelling** (->Digital strategy), **Secondary use of data** (->EHDS), **PFAS** (->Green Deal)
- Shape our future research – Continuously
 - ✓ Send us **ideas aligned with the IHI research agenda** and **requiring a cross-sectoral public-private collaboration**



 ihi.europa.eu





Stay in touch!

Please contact us at:
infodesk@ihi.europa.eu

ihi.europa.eu



ERA4Health Partnership

Joël Groeneveld

Fonds de la Recherche Scientifique–FNRS

ERA4Health Partnership representative

***THCS Annual Conference, 28th-29th November 2024,
Brussels***

ERA4Health Aim and Specific Objectives

ERA4Health fosters European collaborative research funding by creating a flexible funding body for joint programming in priority areas addressing European Public Health Needs and aims to set up Europe at the forefront of science and innovation in Health Research by 2050.

S01. Support relevant medical research including clinical fields and intervention areas

S02. Improve the utilisation of existing health technologies in clinical practice

S03. Build capacity, in particular in conducting IICs at European scale

S04. Implement and develop RRI in multiple ways

ERA4Health Working Plan

Directly related with previous ERA-Nets (ERA-CVD, EuroNanoMed, ERA-HDHL and HDHL-INTIMIC)

Phase
1

PILOT CALL ON IICS (launched at the end of 2024): critical milestone for 2nd phase


Phase
2

- **Calls in research priority areas**
- **Calls for IICS** in Health Technologies addressing public health needs
- Duration: expected **9 years**
- **Incorporation of new funders willing to fund Investigator-Initiated Clinical Studies**

ERA4Health consortia & Strategic Research and Innovation Agenda




37 Partners from 24 countries



ERA4Health: Project structure

Strategic Advisory Board


Ethical and RRI Advisory Board



ERA4Health Joint Transnational Calls (JTCs)

HealthEquity

“Increasing health equity through promoting healthy diets and physical activity”
(JCS:DLR)



10 funded projects with 13M€

“Research targeting the development of innovative therapeutic strategies in cardiovascular disease”
(JCS: ANR)



17 funded projects with 19M€

NutriBrain

“Modulation of brain ageing through nutrition and healthy lifestyle” (JCS:MUR)



15 funded projects with 20M€

NANOTECH

“Nano and advanced technologies for disease prevention, diagnosis and therapy” (JCS:ANR)



19 funded projects with 19M€

Funding of multinational Investigator-Initiated Clinical Studies (IICS)

OPEN CALL EffecTrial: “Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases”

EffecTrial 2025

Now Open!



“Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases”

#EffecTrial_E4H



ERA4Health
Partnership



Co-funded by
the European Union

- Pragmatic randomised interventional comparative effectiveness trials
- Compare the use of currently **approved healthcare interventions** either to each other or to the current **standard of care**.
- **Healthcare interventions** (diagnostic, screening, prevention and treatment interventions), pharmacological or non-pharmacological (e.g. nutrition, surgery, use of medical devices, eHealth...)
- High public relevance only in the fields of these **specific diseases** (potentially including related comorbidities):

- o Cardiovascular diseases

- o Metabolic disorders

- o Nutrition and lifestyle-related diseases

- o Non-communicable respiratory diseases



ERA4Health
Partnership



Co-funded by
the European Union

Development framework for IICS

- Analysis of the **bottlenecks in designing and conducting** multicountry IICS (Deliverable 14.1, approved)
- Mapping of **funding sources available** to fund multicountry IICS in Europe (Deliverable 15.1, approved)
- Mapping of **organisations providing support to multicountry IICS** (Deliverable 15.2, approved)
- **Supporting measures to ensure the quality** of the implementation plans (D17.1, approved)
- **Monitoring measures to follow the conduct of selected Investigator Initiated Clinical Studies** (D17.2, approved)
- **Recommendation booklet for investigators and sponsors** in multicountry IICS (D14.2, submitted)



ERA4Health RRI Guidelines



Responsible Research and Innovation (RRI) - ERA4HEALTH

WHAT IS ERA4HEALTH'S APPROACH TO RRI?

ERA4Health's approach to RRI is focused on improving the quality of research and innovation by keeping the broader context of your work visible. It encourages you to embed methodologies and processes to consider four important dimensions related to research and innovation:



Anticipation. What might the future desirable and undesirable effects of your work be? Who will benefit from it, and who might not? Can decisions be made now to encourage the good, while minimising the bad? This isn't about exhaustive prediction but about building a sense of preparedness for the future.



Inclusion. Whose voices and knowledge are shaping your research project? In health research, much evidence shows that patient organisations, health users and health professionals (amongst others) can improve the quality of innovation. Inclusion is about creating opportunities for two-way exchange of information, co-design or knowledge co-production to draw important outside voices into the research process.



Reflection. Are there opportunities for you and your team to pause and 'take stock' about what you're doing? Would everyone agree with your goals and the decisions you've taken so far? Reflection is about making sure there is space and time to collectively ask hard questions about a project's foundations.



Responsiveness. What are the key decision points in your project? Are there opportunities to change course, if you need to? The final dimension is a reminder that the work you do under the label of RRI needs to shape the design, governance or use of your research or innovation.

Other additional ERA4Health activities

ERA4Health Early Career Network

Publications,
Newsletters,
Communication and
dissemination activities

Capacity Building Activities



ERA4Health
1st webinar



Calum MacRae M.D., PhD
Vice Chair for Scientific Innovation
Department of Medicine
Brigham & Women's Hospital (Boston)
Professor of Medicine at Harvard Medical School

**Building Learning Health Systems for
Discovery, Translation and Care**

Sep 30 13:00-14:00 CET
Registration required



ERA4Health
2nd webinar



Frank Hulstaert M.D.
Senior Researcher
The Belgian Health Care
Knowledge Centre (WICe) [Read More](#)

**Pragmatic Comparative-
Effectiveness Randomized Trials:**

ERA4Health 2nd webinar Pragmatic Comparative-
Effectiveness Randomized Trials: Real-World Evidence for
Better Health Decisions

© 2024-11-11 [Read More](#)

Synergies Working Group



Identification of barriers in translating health research into practical



Co-funded by the European Union

**Help Us Overcome Barriers in
Health Research!**

YOUR INSIGHTS MATTER

**PARTICIPATE IN THE
ERA4HEALTH SURVEY**




Further information in our website:
<https://era4health.eu/>



Thank you!

ERA4Health Coordinator
Institute of Health Carlos III (ISCIII)
ERA4Health@isciii.es

European Partnership One Health AntiMicrobial Resistance



Ulrica Dohnhammar, the Swedish Research Council

Antimicrobial resistance (AMR)?

The ability of microorganisms to withstand substances that are used to kill or control them.

AMR is a global challenge that is threatening the life and health of people and animals, and also economic growth, food safety and sustainable development.

One Health?

A unifying approach balancing the health of people, animals, and ecosystems, and recognising that they are interlinked and interdependent.




In brief

- Co-fund partnership invited in the Horizon Europe work programme 2023/2024
- Continues the legacy of JPIAMR which has been active since 2011
- 10-year programme, starting in the spring 2025
- Annual calls for R&I projects, plus calls for research networks, mobility, and capacity strengthening

The vision of the EUP OHAMR is to reduce the burden of AMR.

This translates to improving the response to the threat of AMR by reducing the spread of AMR in humans, animals and the environment through an integrated OH approach, and by increasing the number of effective treatment options available


Scientific priorities



The focus areas

- Inclusive, real-world challenges
- Invites participation from many scientific disciplines
- Will guide the choice of call topics and set the direction for other activities

Implementation



Consortium

- The Swedish Research Council is the coordinator
- 50 partners:
 - National and regional RFO:s, national ministries
 - Organisations bringing expertise in technical or systems-related matters (e.g. capacity strengthening)
 - Organisations that bring access to civil society, professional and policy networks
- 19 EU members (AT, BE, BG, CZ, DE, DK, EE, ES, FI, FR, IE, IT, LV, LT, MT, NL, PL, PT, SE)
- 8 countries with access to Horizon Europe (CA, IL, MD, NO, ZA, TR, UK, US)
- ... and Switzerland

Key European and global AMR initiatives

- EC, EU agencies (EMA, ECDC, EFSA, EEA)
- Quadripartite Secretariat for One Health, UN agencies (WHO, FAO, UNEP, WOHAI)
- International organisations, e.g. ICARS, CARB-X, GARDP

Resources and experiences to share with other partnerships

- EUP OHAMR WP5 (lead: ZonMw, NL) will develop a FAIR-enabling research data management procedure for the projects funded by the partnership. A pilot study will demonstrate how FAIR research results can be analysed and further exploited with AI-methods beyond the partnership.
- EUP OHAMR WP2 (lead: DLR, DE) is dedicated to relations and synergies with AMR specific and AMR sensitive stakeholders: HE partnerships, JA:s, PPP:s, global collaborations etc.
- Alignment with national programming: AMR strategies and action plans are available on the EU and global levels, and many countries have national action plans (following UN guidance).




Annual THCS Conference

JA NFP4Health

29 November 2024



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.




This presentation at a glance

- **A bit of history**
- **Joint Action NFP4Health**
- **NFP4Health and THCS**




This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.





EU4Health – Synergies & complementarities

An approach by policy area; many instruments contributing to the same objective: health



NFPs : a bit of history

- **Getting started in some MS with PHEA (2006)**
- **First “official” meeting 2008 with 2nd EUHP**
- **Formal provision in 3rd EUHP Regulation**
- **Included in potential actions in EU4Health**



This presentation is part of the action “NFP4Health” which has received funding from the European Union’s Health Programme (2014-2020) under grant agreement No 101035965.



EU4Health : role of NFPs

NFPs are expected to:

- **Assist Health Programme implementation at national level**
- **Assist Health Programme dissemination of results**
- **Provide Information on the impact generated by the Health Programme in their respective countries**




This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.





JANFP4Health



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.


NFP4Health - Joint Action on increasing the capacity of National Focal Points (NFPs)

Funded under the 3rd Health Programme

Duration: 40 months

Deadline: 31.01.2025 (+ 4 months)

Budget: 1,9 M€



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.

General Objective

Create and maintain an innovative ecosystem to facilitate and support European countries in achieving the priorities of the health objectives set for the period 2021-2027.

Specific Objectives


- ✓ To provide input to support the implementation of the future programmeEU4Health programme
- ✓ To orient competent authorities to European programmes that (also) address health and support them in their multi-programme approach.
- ✓ To support the competent authorities in the multi-programme approach within the framework of funding managed at national/regional/local level.
- ✓ To develop the capacity of NFPs with respect to the implementation of the newEU4Health programme and related instruments



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.



JANF4Health's Work Plan



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.



Synergies events organized in the framework of the JA NFP4Health



Showcase event
"Synergies for integrated care"

28-29 October 2024
Spazio Europa, Via Quattro Novembre, 149, 00187 Rome (IT)

On 28 and 29 October, The European Health and Digital Executive Agency (**HaDEA**) is co-organising a showcase event on **"Synergies for integrated care"** in collaboration with the Joint Action on increasing Capacity building for National Focal Points – **JA NFP4Health**, the Horizon Europe Partnership for Transforming HealthCare Systems - **THCS**, the Joint Action on cardiovascular diseases (CVDs) and diabetes – **JACARDI** and the Horizon Europe Health National Contact Points **HNN3.0**.



L'evento avrà luogo presso Spazio Europa, gestito dall'Ufficio del Parlamento europeo in Italia e dalla Rappresentanza in Italia della Commissione europea

Showcase event "Synergies for integrated care" 28th-29th October 2024

"NFPs/NCPs National and European networks: challenges for the creation of synergies on health among European programmes" 21st-22nd November 2023



Event
"NFPs/NCPs National and European networks: challenges for the creation of synergies on health among European programmes"

Rome, 21-22 November 2023

The event, organised in the framework of the JA NFP4Health, aims at promoting and disseminating the project activities that contribute to the EU4Health Programme Implementation. Contextually, the event represents an occasion to strengthen the european networks of National Focal Points (NFP)/National Contact Points (NCP) of other health-related Programmes by highlighting the technical role of the European Programmes 'ambassadors' and pave the way towards the development of synergistic and complementarity actions.

Target: NFPs/NCPs, ProMIS CTO members, Stakeholders

Event open to the wider public in online mode



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.



JA NFP4Health - Webinar Online Synergistic Actions with JA JACARDI February 9, 2024

Meeting objective

- Introduce the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), emphasizing the Work Package 5 on the methodological framework.
- Specifically, highlight task 5.1.1, which involves conducting a context analysis of the Member States.
- Introduce the context analysis, that aims to identify and assess the current status of existing CVD and diabetes prevention and management measures at the country level. This will be achieved through a survey directed towards the National Focal Points of the Member States. The survey will assess governance, financing, and service capacity on specific topics aligned with the technical Work Packages and objectives of JACARDI.



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.



JA NFP4Health towards 2025 (in progress)

		Communication and Dissemination
WP2	T2.1	Dissemination strategy and communication plan
	T2.2	Visual identity and toolkit
	T2.3	Project website, social media and other communications materials
		Evaluation
WP3	T3.1	Definition of the Evaluation and Assessment Plan
	T3.2	Ongoing monitoring
	T3.3	Ongoing Assessment of the fulfilment of specific objectives and added value of the NFP4Health Network
		Sustainability
WP4	T4.1	Sustainability goals specific to EU4Health Programme
	T4.2	Provide training and resources to NFPs and the Network to strengthen their capabilities in strategic planning, effective implementation, and advocacy efforts aimed at ensuring sustainability
	T4.3	Develop and implement a strategy to effectively communicate and promote health priorities across various national frameworks, ensuring alignment with overarching goals and engagement with key stakeholders.
		Networking
WP5	T5.1	NFP4Health Network's Institutionalization
	T5.2	NFP4Health Network's promotional/ambassadorial activities and synergies
		National Focal Point Knowledge Hub
WP6	T6.1	Design and implementation of the NFP Knowledge Hub (KH) built on the Interaction Platform developed under the NFP4Health Joint Action
	T6.2	Capacity Building, Guidance and Contents
	T6.3	Exchange and Assistance
		Tailored support to beneficiary needs at the National level
WP7	T7.1	Needs' assessment for customized support interventions
	T7.2	Development of an applicants' toolkit
	T7.3	Services and events to support beneficiaries at national level

NFP4Health and THCS: Sinergies

- **Coordination Team(s)**
- **Key Partners**
- **Thematic Dissemination (Health systems)**
- **[Scientific support: THCS ➡ NFPs]**
- **[Institutional support: NFPs ➡ THCS]**



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.



**THANK YOU
FOR
YOUR ATTENTION!**

janfp4health.italy@gmail.com



This presentation is part of the action "NFP4Health" which has received funding from the European Union's Health Programme (2014-2020) under grant agreement No 101035965.

